United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

4:01pm BST
Change (% chg)

$0.35 (+3.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Humphrey, Rachel 

Dr. Rachel W. Humphrey, M.D. serves as a Chief Medical Officer of the company. since August 2015, having previously served as a member of our board of directors from May 2015 to August 2015Dr. Humphrey was vice president, head of immuno-oncology at Eli Lilly and Company, a global pharmaceutical company, from May 2015 to August 2015. From November 2013 to December 2014, Dr. Humphrey was vice president, head of immuno-oncology at AstraZeneca, a global pharmaceutical company. From January 2012 to October 2013, she was executive vice president and chief medical officer of Mirati Therapeutics, Inc., where she helped advance multiple assets through early stage clinical investigation. Prior to that, she served as vice president of product development at Bristol-Myers Squibb Company from May 2003 to January 2012. Prior to that, Dr. Humphrey held multiple positions in development at Bayer. Dr. Humphrey began her career as an oncology fellow and staff physician at the National Cancer Institute. Dr. Humphrey received her M.D. from Case Western Reserve University and received her B.A. from Harvard University.

Basic Compensation

Total Annual Compensation, USD 410,800
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,128,900
Fiscal Year Total, USD 1,539,700

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --